ASN 2021 – Glaxo’s daprodustat delivers
But whether data on the novel anaemia pill are clean enough to dispel wider FDA toxicity concerns is hard to call.
Angion’s kidney transplant dream dies
The group will have to pivot to a heart surgery setting, but the omens here are not good. Meanwhile, Vifor’s run of bad luck continues.
Astellas readies roxadustat for launch
But winning EU approval for the novel anaemia pill was not straightforward, the Japanese firm says.
New Glaxo: it’s all about the late-stage assets
Walmsley wins some breathing space but, for ambitious new growth targets to be met, the pipeline must start delivering.
Fibrogen stretches the bounds of credibility
Admission of a major data error in previous roxadustat presentations leaves the novel anaemia pill’s future in doubt.
Adcom pours fresh doubts on roxadustat’s US approvability
Just when investors thought they had seen the worst of it, the delayed Fibrogen/Astrazeneca project faces another problem.
Go or no go? The year ends with Covid-19 vaccine approvals in sight
December promises big US decisions for Novartis, Astrazeneca and Fibrogen, as well as the FDA's first Covid-19 vaccine reviews.
